RARE logo

Ultragenyx Pharmaceutical (RARE) Depreciation And Amortization

Annual D&A

$26.01 M
+$7.79 M+42.73%

31 December 2023

3-Year Change

+96.43%
RARE annual depreciation & amortization is up +96.43% over the past 3 years

All-time High

$26.01 M
RARE annual depreciation & amortization is currently at an all-time high

Sector Rank

80.61%
RARE annual depreciation & amortization is higher than 80.61% of companies in Healthcare sector
Annual Total Expenses$1.00 B
RARE annual total expenses is $1.00 billion
Annual Operating Expenses$958.25 M
RARE annual total operating expenses is $958.25 million
Annual Revenue$434.25 M
RARE annual revenue is $434.25 million
Annual Net Income-$606.64 M
RARE annual net profit is -$606.64 million

RARE Depreciation And Amortization Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly D&A

$8.76 M
-$105.00 K-1.18%

30 September 2024

1-Year Change

+6.56%
RARE quarterly depreciation & amortization is up +6.56% year-on-year

3-Year Change

+147.79%
RARE quarterly depreciation & amortization is up +147.79% over the past 3 years

All-time High

$8.86 M
RARE quarterly depreciation & amortization is currently -1.18% below its historical high of $8.86 million

Sector Rank

82.26%
RARE quarterly depreciation & amortization is higher than 82.26% of companies in Healthcare sector
Quarterly Total Expenses$271.48 M
RARE quarterly total expenses is $271.48 million
Quarterly Operating Expenses$250.46 M
RARE quarterly total operating expenses is $250.46 million
Quarterly Revenue$139.49 M
RARE quarterly revenue is $139.49 million
Quarterly Net Income-$133.52 M
RARE quarterly net profit is -$133.52 million

RARE Quarterly D&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM D&A

$34.68 M
+$1.57 M+4.73%

30 September 2024

1-Year Change

+33.36%
RARE TTM depreciation & amortization is up +33.36% year-on-year

3-Year Change

+161.97%
RARE TTM depreciation & amortization is up +161.97% over the past 3 years

All-time High

$34.68 M
RARE TTM depreciation & amortization is currently at an all-time high

Sector Rank

82.26%
RARE TTM depreciation & amortization is higher than 82.26% of companies in Healthcare sector
Annual Total Expenses$1.00 B
RARE annual total expenses is $1.00 billion
Annual Operating Expenses$958.25 M
RARE annual total operating expenses is $958.25 million
TTM Revenue$522.75 M
RARE TTM revenue is $522.75 million
TTM Net Income-$558.99 M
RARE TTM net profit is -$558.99 million

RARE TTM D&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

RARE Depreciation And Amortization Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-+6.6%+33.4%
3 y3 years+96.4%+147.8%+162.0%
5 y5 years+204.6%+303.7%+306.2%

RARE Depreciation And Amortization High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 yearsat high+96.4%-1.2%+147.8%at high+162.0%
5 y5 yearsat high+204.6%-1.2%+303.7%at high+306.2%
alltimeall timeat high>+9999.0%-1.2%+8401.9%at high>+9999.0%

Ultragenyx Pharmaceutical Depreciation And Amortization History

DateAnnualQuarterlyTTM
Sept 2024
-
$8.76 M(-1.2%)
$34.68 M(+4.7%)
June 2024
-
$8.86 M(+0.2%)
$33.12 M(+11.8%)
Mar 2024
-
$8.85 M(+7.6%)
$29.61 M(+13.9%)
Dec 2023
$26.01 M(+42.7%)
$8.22 M(+14.3%)
$26.01 M(+14.3%)
Sept 2023
-
$7.19 M(+34.1%)
$22.75 M(+12.3%)
June 2023
-
$5.36 M(+2.4%)
$20.25 M(+4.5%)
Mar 2023
-
$5.24 M(+5.6%)
$19.37 M(+6.3%)
Dec 2022
$18.22 M(+37.6%)
$4.96 M(+5.6%)
$18.22 M(+8.5%)
Sept 2022
-
$4.69 M(+4.8%)
$16.80 M(+9.6%)
June 2022
-
$4.48 M(+9.6%)
$15.32 M(+9.7%)
Mar 2022
-
$4.09 M(+15.7%)
$13.96 M(+5.4%)
Dec 2021
$13.24 M(+8.0%)
$3.53 M(+9.9%)
$13.24 M(+3.1%)
Sept 2021
-
$3.22 M(+3.1%)
$12.84 M(+1.0%)
June 2021
-
$3.12 M(-7.3%)
$12.71 M(-0.5%)
Mar 2021
-
$3.37 M(+7.5%)
$12.78 M(+4.2%)
Dec 2020
$12.26 M(+43.6%)
$3.13 M(+1.3%)
$12.26 M(+8.5%)
Sept 2020
-
$3.09 M(-2.9%)
$11.30 M(+9.1%)
June 2020
-
$3.18 M(+11.6%)
$10.35 M(+11.6%)
Mar 2020
-
$2.85 M(+31.5%)
$9.27 M(+8.6%)
Dec 2019
$8.54 M(-56.3%)
$2.17 M(+1.1%)
$8.54 M(-8.3%)
Sept 2019
-
$2.15 M(+1.9%)
$9.31 M(-19.2%)
June 2019
-
$2.11 M(-0.6%)
$11.52 M(-25.6%)
Mar 2019
-
$2.12 M(-28.0%)
$15.50 M(-20.7%)
Dec 2018
$19.54 M
$2.94 M(-32.4%)
$19.54 M(+2.2%)
DateAnnualQuarterlyTTM
Sept 2018
-
$4.36 M(-28.4%)
$19.11 M(+20.6%)
June 2018
-
$6.08 M(-1.3%)
$15.85 M(+46.4%)
Mar 2018
-
$6.16 M(+145.0%)
$10.82 M(+85.8%)
Dec 2017
$5.83 M(+70.1%)
$2.51 M(+129.6%)
$5.83 M(+30.4%)
Sept 2017
-
$1.09 M(+3.8%)
$4.47 M(+1.5%)
June 2017
-
$1.05 M(-9.1%)
$4.40 M(+9.0%)
Mar 2017
-
$1.16 M(+0.3%)
$4.04 M(+18.0%)
Dec 2016
$3.42 M(+147.4%)
$1.16 M(+12.2%)
$3.42 M(+24.6%)
Sept 2016
-
$1.03 M(+49.0%)
$2.75 M(+27.4%)
June 2016
-
$692.00 K(+27.2%)
$2.16 M(+24.9%)
Mar 2016
-
$544.00 K(+13.3%)
$1.73 M(+24.8%)
Dec 2015
$1.38 M(+102.3%)
$480.00 K(+8.8%)
$1.38 M(+24.0%)
Sept 2015
-
$441.00 K(+68.3%)
$1.12 M(+28.4%)
June 2015
-
$262.00 K(+30.3%)
$869.00 K(+13.2%)
Mar 2015
-
$201.00 K(-5.2%)
$768.00 K(+12.3%)
Dec 2014
$684.00 K(+54.1%)
$212.00 K(+9.3%)
$684.00 K(+17.1%)
Sept 2014
-
$194.00 K(+20.5%)
$584.00 K(+18.0%)
June 2014
-
$161.00 K(+37.6%)
$495.00 K(+13.3%)
Mar 2014
-
$117.00 K(+4.5%)
$437.00 K(-1.6%)
Dec 2013
$444.00 K(+41.9%)
$112.00 K(+6.7%)
$444.00 K(+33.7%)
Sept 2013
-
$105.00 K(+1.9%)
$332.00 K(+46.3%)
June 2013
-
$103.00 K(-16.9%)
$227.00 K(+83.1%)
Mar 2013
-
$124.00 K
$124.00 K
Dec 2012
$313.00 K(+820.6%)
-
-
Dec 2011
$34.00 K
-
-

FAQ

  • What is Ultragenyx Pharmaceutical annual depreciation & amortization?
  • What is the all time high annual D&A for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical quarterly depreciation & amortization?
  • What is the all time high quarterly D&A for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical quarterly D&A year-on-year change?
  • What is Ultragenyx Pharmaceutical TTM depreciation & amortization?
  • What is the all time high TTM D&A for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical TTM D&A year-on-year change?

What is Ultragenyx Pharmaceutical annual depreciation & amortization?

The current annual D&A of RARE is $26.01 M

What is the all time high annual D&A for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high annual depreciation & amortization is $26.01 M

What is Ultragenyx Pharmaceutical quarterly depreciation & amortization?

The current quarterly D&A of RARE is $8.76 M

What is the all time high quarterly D&A for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high quarterly depreciation & amortization is $8.86 M

What is Ultragenyx Pharmaceutical quarterly D&A year-on-year change?

Over the past year, RARE quarterly depreciation & amortization has changed by +$539.00 K (+6.56%)

What is Ultragenyx Pharmaceutical TTM depreciation & amortization?

The current TTM D&A of RARE is $34.68 M

What is the all time high TTM D&A for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high TTM depreciation & amortization is $34.68 M

What is Ultragenyx Pharmaceutical TTM D&A year-on-year change?

Over the past year, RARE TTM depreciation & amortization has changed by +$8.68 M (+33.36%)